Josep M. Domingo Domenech, M.D., Ph.D.

Location

Contact

SUMMARY

Josep M. Domingo Domenech, M.D., Ph.D., researches the molecular and cellular pathogenesis of prostate and bladder cancers. He uses in vitro and in vivo experimental mouse models together with human datasets. Dr. Domingo Domenech functionally dissects the genes and pathways involved in the initiation, therapy response and aggressiveness of cancer. He studies the cellular heterogeneity of tumors to identify the molecular pathways that allow a subset of drug-tolerant cancer cells to survive therapy. His research program comprehensively integrates orthogonal experimental data using computational tools to develop novel anti-tumor therapeutic approaches. These approaches determine new molecular surrogates of clinical outcome.

Focus areas

• Dissect the role of master transcription and epigenetic factors in lethal prostate cancer.
• Investigate the role of translational reprogramming in advanced prostate cancer.
• Define actionable vulnerabilities of drug-tolerant cancer stem cells in prostate cancer and other tumor types.
• Develop and study derived xenograft and organoid platforms in prostate cancer, bladder cancer and other tumors.
• Discover new targetable pathways of bladder cancer that progresses with standard therapy.

Significance to patient care

Dr. Domingo Domenech strives to determine the mechanisms responsible for the progression of cancer to metastatic and therapy-resistant stages. Finding these mechanisms helps in discovering new treatments and developing new strategies to better assess the risk of cancer death.

Professional highlights

• Director, Urology Translational Research, Mayo Clinic, 2022-present.